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Influence of surveillance renal allograft biopsy on diagnosis
and prognosis of polyomavirus-associated nephropathy.
Background. Polyomavirus-associated nephropathy (PVAN)
is an increasingly prevalent cause of allograft dysfunction.
Methods. In 18 histologically proven cases of PVAN man-
aged by reduced immunosuppression, monitoring of serum cre-
atinine, and repeated biopsy, graft outcomes were correlated
with clinical and histologic indices. Six months postdiagnosis
the status of each graft was classified as poor (N  7) or
satisfactory (N  11). Poor transplant status was defined as
graft loss, increased severity of PVAN on repeat biopsy, or
serum creatinine 3.0 mg/dL. Diagnosis resulted from either
surveillance allograft biopsies (N  8) or biopsies performed
for increased serum creatinine (nonsurveillance, N  10).
Results. The surveillance biopsy group was more likely than
the nonsurveillance group to have satisfactory graft status at
6 months (eight of eight vs. three of ten, P  0.004) and had
significantly lower serum creatinine at diagnosis, 3, and 6 months.
Histologic scoring for chronic interstitial and tubular injury
was lower in diagnostic surveillance biopsies compared to non-
surveillance biopsies (P  0.01). Satisfactory transplant status
was also associated with reduced or absent virus on repeat
biopsy (P  0.01). Poor transplant status was associated with
a higher frequency of recipientneg/donorpos cytomegalovirus
(CMV) serology (71% vs. 9%, P  0.01).
Conclusion. Surveillance allograft biopsy provides an im-
portant means for earlier detection of PVAN and permits
timely alterations to immunosuppression. Early diagnosis is
associated with a lesser degree of interstitial fibrosis at diagno-
sis and lower baseline and subsequent serum creatinine.
Polyomavirus-associated nephropathy (PVAN), caused
by the BK virus (BKV) subtype, has emerged over the
last 3 years as a postrenal transplant infection with im-
portant effects [1–6]. Within this short period of time, it
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has been reported from transplant centers in the United
States and Europe that between 3% and 5% of renal
transplant recipients now develop PVAN with rates of
graft loss as high as 40% among those affected [6–12].
The disease typically presents as increased serum creati-
nine and is confirmed by a graft biopsy demonstrating
cytopathic change of renal tubular epithelial cells accom-
panied by an interstitial inflammatory infiltrate of vari-
able severity [6–9, 11]. BKV can be specifically detected
within graft tissue by in situ hybridization or immunohis-
tochemistry and in serum by polymerase chain reaction
(PCR). The presence of virally loaded cells can also be
detected in urine by cytologic or by electron microscopic
techniques [6–19]. Treatment has remained a challenge
as no prophylactic therapy exists and the single antiviral
agent for which some efficacy has been reported (cidofo-
vir) has significant renal toxicity [abstract; Tzuner et al,
Am J Transplant (Suppl 1):S270, 2000]. While reduction
in immunosuppression remains the standard of care,
many patients enter a disheartening cycle of alternating
PVAN, acute rejection, and progressive graft dysfunc-
tion [8]. As proposed by Nickeleit et al [8, 20], a strategy
for identification of patients at risk for PVAN and diag-
nosis of the condition prior to the development of graft
injury will be essential for reducing the future impact
of this infection and may be associated with complete
histologic resolution.
Primary infection with BKV typically occurs in early
childhood with an adult seroprevalence rate of 80% [6–9,
21]. The virus remains latent in urothelium and reactiva-
tion is often the result of immunosuppression. Following
renal transplantation, asymptomatic shedding of virally
loaded urothelial “decoy” cells can be detected in the
urine in 10% to 30% of recipients [6–9]. With such a
large proportion of graft recipients at theoretical risk for
PVAN, it is not feasible to reduce immunosuppression
or carry out trials of potentially toxic antiviral agents in
all individuals with evidence of viral exposure or of viral
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activity within the urothelium. The identification of pa-
tients in whom the disease has progressed to the stage
of viral activity within renal tubular epithelial cells is
central, therefore, to understanding the safety and effi-
cacy of currently available therapeutic interventions for
PVAN. The most appropriate means to carry out surveil-
lance for clinically significant BKV activity remains to
be determined.
The factors influencing clinical outcomes following di-
agnosis of PVAN are also poorly understood at present.
While earlier studies report high rates of graft loss [1–6],
it is likely that these represent predominantly advanced
cases. With a growing awareness of PVAN among renal
transplant physicians and pathologists as well as the in-
troduction of more sensitive diagnostic modalities, it is
likely that the clinical disease spectrum and range of out-
comes is broadening [9, 11]. While a number of studies
have addressed the utility of different diagnostic modal-
ities to more readily detect PVAN [10–19], none to our
knowledge has examined the importance of early histo-
logic disease diagnosis in regards to graft outcome. We
report here that the diagnosis of PVAN at a subclinical
level by surveillance renal allograft biopsy is associated
with significantly improved graft prognosis compared
with cases diagnosed by nonsurveillance biopsy during
the same time period and managed by similar reductions
in immunosuppression. Our results highlight the prog-
nostic importance of early PVAN detection and, with
the emergence of this disease as a major cause of graft
injury, provide additional supportive evidence for the
clinical utility of surveillance renal allograft biopsy.
METHODS
Patient population and identification of PVAN cases
Between September 1996 and December 2001, a total
of 672 kidney transplants were performed at Mayo Clinic,
Rochester. Surveillance allograft biopsies were performed
in all consenting graft recipients at 3 to 4 months and at
12 months posttransplantation. Additional (nonsurveil-
lance) biopsies were performed as clinically indicated for
unexplained increases in serum creatinine. Biopsies were
evaluated by two renal pathologists utilizing standard
light microscopy. A diagnosis of PVAN was suspected
in biopsies showing focal interstitial mononuclear in-
flammatory cell infiltrates, dilated tubules with necrotic
tubular epithelium, and homogeneous intranuclear in-
clusion bodies. In situ hybridization for BKV DNA was
performed on paraffin-embedded tissue sections from
all biopsies for which light microscopic findings were
suspicious for PVAN. The tissue sections were deparaf-
finized and treated with proteinase K, following which
a biotin-labeled BKV-specific cDNA probe (Enzo Diag-
nostics, Inc., Farmingdale, NY, USA) or an appropriate
negative control probe were applied. After hybridiza-
tion, streptavidin-alkaline phosphatase was applied and
the hybridization product was visualized by bromo-4-
chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/
NBT) colorimetric reaction. The specificity of the in situ
hybridization assay was validated by demonstration of
negative staining on tissue samples know to be positive
for JC virus (JCV), Epstein-Barr virus (EBV), and cyto-
megalovirus (CMV). Eighteen patients in whom a renal
allograft biopsy demonstrated histologic features diag-
nostic of PVAN were identified. Five of the renal allo-
graft biopsies that were positive for BKV by in situ hy-
bridization were negative when hybridized with probes
for EBV and CMV.
Clinical management and follow-up of PVAN cases
Following the diagnosis of PVAN, stepwise reduction
in immunosuppression was carried out. Immunosuppres-
sion changes consisted of (1) reduction of baseline myco-
phenolate mofetil dosage (typically 1 g or 750 mg twice
daily) by increments of 250 mg twice daily every 2 weeks
to a baseline dose of between 500 mg twice daily and 0
mg, and (2) reduction in tacrolimus from baseline target
trough range (8 to 10 ng/mL or 6 to 10 ng/mL depending
on time from transplantation) to a target trough level of
between 5 and 7 ng/mL or conversion from tacrolimus
to cyclosporine with a target trough level of between
125 and 175 mg/mL. Prednisone dosages were unchanged
and were between 5 mg and 10 mg daily. Measurements
of serum creatinine were performed weekly following
diagnosis for the first 12 weeks, twice monthly for 3
months, then monthly thereafter. Repeated biopsies to
ascertain disease status were obtained between 3 and 6
months postdiagnosis in all but five cases, two of whom
suffered early graft loss.
Histologic scoring for PVAN severity and chronicity
The severity of BK graft infection by in situ hybridiza-
tion was graded on a scale of 0 to 5 for all diagnostic
and follow-up biopsies. Grading was as follows: 0  no
evidence of disease, 1  mild disease (nuclear positivity
in 10 or fewer tubular cross-sections), 2mild-moderate
(nuclear positivity in 11 to 20 tubular cross-sections),
3  moderate (nuclear positivity in 21 to 30 tubular
cross-sections), 4  moderate-severe (nuclear positivity
in 31 to 40 tubular cross-sections), and 5 severe disease
(nuclear positivity in greater than 40 tubular cross-sec-
tions). The severity of chronic tubular, interstitial, and
vascular changes were scored using standard Banff crite-
ria for chronic renal allograft injury based on the degree
of interstitial fibrosis, tubular atrophy, arterial fibrous
intimal thickening, and hyaline arteriolosclerosis [22].
Data acquisition and statistical analysis
Demographic, clinical, and laboratory data were as-
similated in a retrospective fashion on all patients diag-
nosed with PVAN by review of clinical records. Statisti-
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Fig. 1. Diagnosis of polyomavirus-associated nephropathy (PVAN)
among renal transplants according to year of transplant. For each year
between 1997 and 2000, the percentage of total renal transplant recipi-
ents that subsequently received a diagnosis of histologically proven
PVAN on or before December 31, 2001 was calculated. A sequential
increase in the frequency of PVAN is graphically demonstrated.
cal analysis was performed using the SAS software
package (SAS Institute, Inc., Cary, NC, USA). The level
of statistical significance for all tests was set at P value of
0.05. The Wilcoxon rank sum test was used to compare
medians in independent populations and Fisher’s exact
test for two by two table associations. Results are pre-
sented as counts and percentages for qualitative data
and mean  SD for quantitative data.
RESULTS
Characteristics of PVAN among renal
transplant recipients
A total of 18 cases of PVAN were diagnosed on the
basis of characteristic histopathologic features on renal
allograft biopsy and positive in situ hybridization be-
tween January 1999 and December 2001. The patients
had received their renal transplants between September
1996 and August 2001. Three patients were multiple
organ recipients. One had received a combined liver/
kidney transplant, another a living donor kidney trans-
plant followed by a cadaveric pancreas transplant, and
a third a living donor kidney following a heart transplant.
As shown in Figure 1, when the proportion of total renal
transplant recipients for each year between 1997 and
2000 who were subsequently diagnosed with PVAN was
determined, there was a clear trend toward an increasing
occurrence of the disease within our practice. Of the
individuals who received a renal transplant in 2000,
4.25% have, to date, developed histologically proven
PVAN. Demographic and clinical characteristics for the
18 cases are summarized in Table 1. Of note, the low
proportion of cadaveric donor transplants (28%) reflects
Table 1. Characteristics of 18 patients with polyomavirus-associated
nephropathy (PVAN)
Age meanSD 56.814.4
Male number (%) 12 (67)
Cadaveric transplant number (%) 5 (28)
Number of MHC mismatches meanSD 2.61.9
CMV recipient () at time of transplantation
number (%) 7 (39)
Antibody induction number (%) 10 (56)
Immunosuppressive medications prior to PVAN
number (%)
Prednisone 18 (100)
Tacrolimus 18 (100)
Cyclosporine 4 (22)
Mycophenolate mofetil 16 (89)
Sirolimus 4 (22)
Acute rejection prior to PVAN diagnosis number (%) 5 (28)
Months posttransplant to PVAN diagnosis meanSD 13.811
Acute rejection after PVAN diagnosis number (%) 4 (22)
Poor transplant status 6 months following PVAN
diagnosisa 8 (40)
Abbreviations are: MHC, major histocompatibility complex; CMV, cytomega-
lovirus.
aSee text for definition of poor transplant status
the predominance of living donation in our practice and,
during this time period, the prevalence of PVAN was
similar in both cadaveric (2.2%) and living (2.6%) donor
allograft recipients. Other pretransplant characteristics
of the group, including age, gender, number of major
histocompatibility complex (MHC) mismatches, and se-
rologic status for CMV were also comparable with our
total cohort of renal transplant recipients. Regarding
immunosuppressive therapy, all 18 patients had received
tacrolimus and prednisone prior to the diagnosis of PVAN
and the majority (89%) had received mycophenolate
mofetil. Of the four patients who had received cyclospo-
rine, two had been changed to tacrolimus before devel-
oping PVAN. Of the four who had received sirolimus,
three had been changed to tacrolimus and one was re-
ceiving a combination of sirolimus and tacrolimus. A
majority (56%) had received some form of antibody
induction at the time of transplantation, a proportion
in keeping with the overall employment of induction
therapy at our institution during the same time period.
The frequency of acute rejection prior to diagnosis of
PVAN was 28%.
Four patients (22%) were diagnosed with acute rejec-
tion within 6 months following PVAN diagnosis. Three
of these had required treatment for acute cellular rejec-
tion prior to PVAN diagnosis. Acute rejection following
PVAN was diagnosed when BKV was absent by in situ
hybridization but significant mononuclear cell infiltrates
with tubulitis were present (N 2) or when viral involve-
ment was clearly diminished but mononuclear cell infil-
trates with tubulitis were increased (N  2). Three of
four patients with acute rejection were treated with ste-
roid bolus therapy, followed by moderate increase in
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Fig. 2. Time intervals between renal transplantation and diagnosis of
histologically proven polyomavirus-associated nephropathy (PVAN)
according to year of transplantation. Mean intervals are shown as hori-
zontal bars and individual cases as circles. Open circles denote cases
diagnosed by nonsurveillance biopsy; closed circles denote cases diag-
nosed on surveillance biopsy.
baseline oral immunosuppression and one was treated
by increased oral immunosuppression only. To date, two
patients have retained stable graft function without evi-
dence of PVAN recurrence and two have suffered graft
loss.
The mean interval between transplantation and diag-
nosis of PVAN was 13.8 months; however, as shown in
Figure 2, there has been a clear trend toward more early
diagnoses for patients transplanted in 1999 or later com-
pared to those transplanted between 1996 and 1998. For
the 11 cases occurring in patients who received a renal
transplant in 2000 or 2001, the mean time of diagnosis
was 9.3 months posttransplant compared with 10 months
for those transplanted in 1999 and 35.3 months prior to
1999. The lack, to date, of later cases among the 1999
cohort suggests that diagnosis within the first year is now
characteristic of PVAN.
Effect of PVAN on renal allograft function
Following histologic diagnosis, patients with PVAN
were managed by step-wise reductions in immunosup-
pression and close follow-up of graft function. Repeat
allograft biopsy within the first 6 months following diag-
nosis was carried out in 13 cases. In order to stratify the
cases according to the impact of PVAN diagnosis on
renal graft function, we divided the patients into those
with satisfactory transplant status and those with poor
transplant status at 6 months following histologic diagno-
sis. Poor transplant status was defined as one or more
of the following: (1) graft loss, (2) increased severity of
PVAN histologic features on repeat allograft biopsy, or
(3) serum creatinine greater than 3.0 mg/dL at 6 months
following diagnosis. Satisfactory transplant status was
defined as (1) histologic improvement in PVAN on re-
peat biopsy and/or (2) stable serum creatinine of less
than 3.0 mg/dL at 6 months following diagnosis. By these
criteria, seven cases (39%) were characterized as having
poor and 11 (61%) as having satisfactory transplant sta-
tus. A comparison of the two groups is presented in
Table 2. As shown, there were no significant differences
between the groups for age, gender, source of donor
organ, MHC mismatches, acute rejection prior to PVAN
diagnosis, or exposure to individual oral immunosup-
pressive agents. Although there was a trend toward later
diagnosis in patients with subsequent poor transplant
status compared to those with satisfactory status, this
did not reach statistical significance. Patients with poor
status at 6 months postdiagnosis were significantly more
likely to have recipientneg/donorpos CMV serologic status
pretransplant (71% vs. 9%, P  0.01), and were less
likely to have received antibody induction therapy (17%
vs. 82%, P  0.01) or to have improvement in histologic
features of PVAN on follow-up biopsy (40% vs. 100%,
P  0.04). Strikingly, while 73% of the patients with
subsequent satisfactory transplant status had the diagno-
sis of PVAN made first on a surveillance allograft biopsy,
none of the patients with subsequent poor transplant
status were diagnosed from a surveillance biopsy (P 
0.004). An example of the histologic changes of PVAN
from a surveillance renal allograft biopsy is shown in
Figure 3.
Diagnosis of PVAN by surveillance renal allograft
biopsy is associated with improved graft outcomes
and reduced chronic interstitial graft injury
A comparative analysis of baseline characteristics,
graft function following the reduction of immunosup-
pression, and histologic indices of graft injury was carried
out for patients in whom PVAN was diagnosed by sur-
veillance and nonsurveillance biopsy (Table 3). Nonsur-
veillance biopsy diagnosis was, on average, made later
following transplantation than surveillance biopsy diag-
nosis (18.2  13.8 months vs. 7.6  4.7 months) but this
did not reach statistical significance. The groups also did
not differ significantly with regard to donor source, prior
acute rejection, use of antibody induction, or exposure
to individual oral immunosuppressants. In contrast, how-
ever, all surveillance cases were associated with satisfac-
tory transplant status at 6 months postdiagnosis compared
with only 30% of the nonsurveillance cases (P  0.04).
This observation was reinforced by a comparison of se-
rum creatinine concentrations between both subsets at
baseline, 3, and 6 months postdiagnosis (Figure 4). As
shown, mean serum creatinine was significantly lower at
each time point in the surveillance group. In the nonsur-
veillance group, there was a trend toward progressive
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Table 2. Clinical characteristics of polyomavirus-associated nephropathy (PVAN) cases according to graft function at 6 months postdiagnosis
Poor transplant Satisfactory transplant
status (N  7)a status (N  11)a P value
Months posttransplant to PVAN diagnosis meanSD 19.915.5 9.96.9 0.27
Age meanSD 55.011.0 57.316.6 0.62
Male number (%) 4 (57) 8 (73) 0.63
Cadaveric transplant number (%) 3 (43) 2 (18) 0.32
CMV recipientneg at transplantation number (%) 5 (71) 2 (18) 0.05
CMV recipientneg donorpos at transplantation number (%) 5 (71) 1 (9) 0.01
Number of MHC mismatches meanSD 2.72.2 2.41.9 0.68
Available follow-up months (meanSD) 15.47.1 10.58.0 0.13
Antibody induction number (%) 1 (17) 9 (82) 0.01
Acute rejection prior to PVAN number (%) 3/5 (60) 2/10 (20) 0.25
Antibody for rejection prior to PVAN number (%) 2/5 (40) 2/10 (20) 0.56
Immunosuppression prior to PVAN number (%)
Prednisone 7 (100) 11 (100) 1.00
Tacrolimus 7 (100) 11 (100) 1.00
Cyclosporine 3 (43) 1 (9) 0.24
Mycophenolate mofetil 6 (86) 10 (91) 1.00
Sirolimus 2 (29) 2 (18) 1.00
PVAN improved on repeat biopsy number (%) 2/5 (40)b 8/8 (100)c 0.04
Diagnosis made on surveillance biopsy 0/7 (0) 8/11 (73) 0.004
Abbreviations are: CMV, cytomegalovirus; MHC, major histocompatibility complex.
aTransplant status 6 months following histologic diagnosis of PVAN
bNo repeat biopsy carried out in two cases
cNo repeat biopsy carried out in three cases
increase in serum creatinine during the 6 months follow-
ing PVAN diagnosis with graft loss occurring in two
patients (represented graphically as a creatinine value
of 7 mg/dL).
The histologic features of PVAN at the time of diagno-
sis were compared for surveillance and nonsurveillance
cases (Table 4). All biopsies were considered adequate
by Banff criteria. The extent of viral infection of tubular
epithelium was scored using a PVAN severity index (see
the Methods section). The mean score at diagnosis was
not significantly higher for nonsurveillance as compared
to surveillance biopsy cases (3.00 vs. 2.14, P  0.32). In
contrast, using Banff criteria, indices of chronic intersti-
tial and tubular injury were significantly higher at the
time of diagnosis for nonsurveillance as compared to
surveillance cases (interstitial chronicity, 2.20  0.92 vs.
1.00  0.63, P  0.02; tubular chronicity, 2.40  0.84 vs.
1.3  0.52, P  0.02). For six of the nonsurveillance
cases and seven of the surveillance biopsy cases a follow-
up biopsy was carried out between 3 and 6 months fol-
lowing PVAN diagnosis. Strikingly, a significant reduc-
tion in the PVAN severity score between diagnosis and
follow-up biopsy was observed for surveillance biopsy
cases (2.14  1.94 vs. 0.75  0.96, P  0.05), whereas
PVAN severity was essentially unchanged for the non-
surveillance biopsy group (3.00  1.63 vs. 3.00  2.00).
Four cases were encountered for which in situ hybridiza-
tion for BKV was negative on the repeat biopsy. All
of these cases occurred within the group diagnosed by
surveillance biopsy. There were also four cases, all within
the nonsurveillance biopsy group, for which PVAN se-
verity was increased on repeat biopsy. Although the
Fig. 3. An example of histologic injury due to polyomavirus-associated
nephropathy (PVAN) on a surveillance renal allograft biopsy. A renal
allograft surveillance biopsy at 1-year posttransplant demonstrates
dense interstitial mononuclear infiltration and cytopathic changes of
multiple tubular epithelial cells suggestive of PVAN (large arrows). In
situ hybridization for BKV DNA confirms the diagnosis with nuclear
positivity of individual cells from multiple tubular cross-sections (small
arrows). The patient was a 43-year-old woman who had received a
living unrelated donor renal transplant. At the time of biopsy, serum
creatinine was stable at 1.5 mg/dL.
numbers of cases of histologically confirmed “viral clear-
ance” and “viral progression” did not allow for a detailed
comparison, the observation emphasizes the potential
for elimination of BKV from the graft in the context of
early diagnosis as well as the importance of follow-up
biopsy in determining the success of interventional strat-
egies [20]. Additional histologic analyses that were car-
ried out on baseline and follow-up biopsies included
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Table 3. Clinical characteristics of polyomavirus-associated nephropathy (PVAN) cases according to diagnostic modality
Surveillance Nonsurveillance
biopsy (N  8) biopsy (N  10) P value
Months posttransplant to PVAN diagnosis meanSD 7.64.7 18.213.8 0.08
Cadaveric transplant number (%) 1 (12.5) 4 (40) 0.31
Acute rejection prior to PVAN diagnosis number (%) 2 (25) 3 (30) 1.00
Antibody induction number (%) 6 (75) 5 (50) 0.37
Immunosuppression prior to PVAN number (%)
Prednisone 8 (100) 10 (100) 1.00
Tacrolimus 8 (100) 10 (100) 1.00
Cyclosporine 1 (12.5) 3 (30) 0.58
Mycophenolate mofetil 7 (87.5) 9 (90) 1.00
Sirolimus 1 (12.5) 2 (20) 1.00
Poor transplant status 6 months following PVAN diagnosis number (%) 0/8 (0) 7/10 (70) 0.04
Fig. 4. Serum creatinine values at baseline and during follow-up are
significantly lower for cases diagnosed by surveillance biopsy compared
to nonsurveillance biopsy. Serum creatinine at the time of histologic
diagnosis of polyomavirus-associated nephropathy (PVAN) and at 3
and 6 months postdiagnosis are shown for cases diagnosed by non-
surveillance biopsy (open circles) and by surveillance biopsy (closed
circles). Cases in which graft loss occurred are represented graphically
as having serum creatinine of 7.0 mg/dL at 6 months. Mean values
for the groups at each time point are represented as horizontal bars.
Significantly lower mean serum creatinine values were observed for
protocol compared with nonprotocol cases at diagnosis as well as at
the two follow-up time points.
Banff scoring for acute and chronic glomerular and vas-
cular injury. For these analyses no significant differences
were observed between surveillance and nonsurveillance
biopsies (data not shown). Despite stable creatinine val-
ues and frequent apparent elimination of intragraft BKV
during the follow-up period, there was a trend toward
increased tubular chronicity on follow-up biopsy for cases
diagnosed by surveillance biopsy.
DISCUSSION
The most significant finding of this report is the supe-
rior prognosis for PVAN in renal transplant recipients in
whom the diagnosis was made on a surveillance allograft
biopsy. Importantly, the cases identified from surveil-
lance and nonsurveillance biopsies were diagnosed dur-
ing the same recent time period, received similar immu-
nosuppressive management both before and after the
diagnosis of PVAN, and did not have significantly differ-
ent initial viral burden based on in situ hybridization. In
fact, the two groups primarily differed at the time of
diagnosis with regard to serum creatinine and degree of
tubulointerstitial scarring. Although these findings sug-
gest that histologic diagnosis of PVAN at an early stage
can prevent subsequent irreversible graft injury, we can-
not entirely rule out the possibility that the two groups
differ in other respects such as initial viral burden, viral
strain, or genetic predisposition to aggressive disease.
The fact that the prevalence of PVAN in our practice
over the past 3 years closely parallels reported rates from
centers in which all cases are associated with increased
serum creatinine [6, 9–12] suggests, however, that the
cases diagnosed by surveillance biopsy in this study
would eventually have manifested graft dysfunction as
a result of PVAN. We interpret these observations, there-
fore, as a strong indication that the diagnosis of PVAN
prior to the onset of clinical graft dysfunction is both
feasible and desirable.
Our results can also be viewed in the context of a
growing appreciation that clinically manifest graft injury
may be preceded by detectable subclinical disease and
that intervention during this phase may beneficial [23, 24].
Hirsch [9] and Nickeleit et al [3, 8, 20] have proposed a
model of PVAN pathogenesis in which asymptomatic
urinary viral shedding is followed by early graft invasion
with detectable viremia and, subsequently, by clinical
graft dysfunction with overt histologic disease. Consis-
tent with this model there is evidence for a predictable
histologic sequence in PVAN with the earliest stage con-
sisting of cytopathic changes within clusters of medullary
tubular epithelial cells [9, 11, 25]. Progression of the dis-
ease process is characterized by viral invasion of all tubu-
lar sections with associated tubular degeneration and
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Table 4. Histologic staging at diagnostic and 3-month follow-up biopsy in patients with polyomavirus-associated nephropathy (PVAN)
Diagnostic biopsy Follow-up biopsy
Nonsurveillance Surveillance Nonsurveillance Surveillance
(N  10) (N  8) P valuea (N  6) (N  7) P valuea
PVAN severity index 3.001.63 2.141.95 0.34 3.002.00 0.750.96 0.08
Interstitial chronicity index 2.200.92 1.000.63 0.01 2.300.80 1.300.96 0.09
Tubular chronicity index 2.40.84 1.300.52 0.01 2.200.80 2.000.82 0.75
aTwo-sample test, equal variance
inflammatory infiltrates. A late stage, in which tubular
atrophy and interstitial fibrosis are predominant and viral
cytopathic changes infrequent, may be indistinguishable
from chronic allograft nephropathy. Drachenberg et al
[11], in an extensive series of biopsy-proven cases, pro-
vide clear examples of this histologic progression. Fur-
thermore, in a series of cynomolgous monkeys immuno-
suppressed for experimental transplantation, Van Gorder
et al [25] have described similar histologic stages for a
simian PVAN that closely resembles the human disease.
Interestingly, in these monkeys, the timing of histologic
onset in renal allografts appeared to occur predictably
between 3 and 8 weeks after transplantation. Our obser-
vation that biopsies carried out after a rise in serum
creatinine contain significantly more chronic tubulo-
interstitial scarring is in keeping with this model of pro-
gression and we propose that a substantial proportion
of PVAN cases can be detected prior to the onset of graft
dysfunction by appropriately timed surveillance biopsies.
The invasive nature of an allograft biopsy raises the
important question of whether a noninvasive assay can
be employed to provide similar early diagnosis of PVAN.
This has been the focus of a number of recent reports
in which the correlation between histologic PVAN and
blood or urine testing for BKV has been examined [10-
12, 16-19] [abstract; Vats et al, Transplantation (Suppl
69):S136, 2000]. The presence of decoy cells in urine
appears to be an invariable finding at the time of histo-
logic PVAN diagnosis, and has an excellent negative
predictive value [8, 9, 11]. Nickeleit et al [8] have sug-
gested that urine cytology can be used as a first-line
screening test to identify individuals requiring further
monitoring. PCR testing of urine has been examined
prospectively by several investigators [17, 19]. Ding et
al [19] have reported that sequential quantitative PCR
of urine may identify a “threshold viral load” for pre-
dicting the occurrence of PVAN. Two recent studies have
demonstrated the presence of BKV in blood samples by
PCR at the time of histological diagnosis of PVAN [10, 16].
These reports also showed clearly that detectable BKV
in blood can predate the development of histologic
PVAN and that reduction in immunosuppression can
be rapidly followed by disappearance of virus from the
blood. More recently, Hirsch et al [12] have demonstrated
prospectively that BK viremia can be detected in 13% of
renal allograft recipients during the first 2 years following
transplantation. While these observations support the
use of surveillance by blood PCR as a sensitive means
to identify recipients at heightened risk for PVAN, it is
not yet clear whether reduction in immunosuppression
is justified at the time of a first positive blood test if a
biopsy proves negative. Clearly, additional prospective
studies involving large patient numbers will be needed
to develop robust screening strategies to identify recipi-
ents in the early stages of graft involvement while avoid-
ing immunosuppression reduction or antiviral use in those
with nonpathogenic viruria or viremia.
The recent emergence of PVAN is likely a reflection
of the use of newer, more potent immunosuppressive
regimens [2–9]. Whether one or more of these immuno-
suppressants is specifically responsible for fostering BK
viral invasion of renal tubular epithelium remains less
clear [9]. As with the majority of reported cases, our pa-
tients have predominantly received a tacrolimus/myco-
phenolate–based immunosuppressive regimen. However,
in common with other studies, we cannot formally as-
cribe increased risk to one agent or combination. The
issue of disease prognosis under different immunosup-
pressive regimens also remains unexplored. Interestingly,
we find that the use of antibody induction was associated
with significantly less risk of poor transplant status 6
months following PVAN diagnosis. This is in contrast
to the reported poor prognosis of PVAN following the
use of antibody therapy for acute rejection [3, 5]. As
prior acute rejection has been commonly reported in
clinically severe PVAN, it is possible that induction ther-
apy, by reducing early acute rejection, is associated with
less graft injury at the time of viral invasion. It is to
be hoped that for some emerging immunosuppressive
agents the risk of BKV reactivation will be reduced.
The interaction between CMV infection and other
causes of graft injury continues to be a significant consid-
eration in organ transplant recipients [26–30]. It is of
interest, therefore, that our analysis suggests an associa-
tion between the recipientneg/donorpos serologic profile
for CMV and poor graft outcome following PVAN diag-
nosis. Nonetheless, in a recent report by Hirsch et al [12],
no temporal association could be demonstrated between
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BKV replication and CMV antigenemia in prospectively
screened renal transplant recipients. Further prospective
studies involving large groups of patients will be required
to determine whether the clinical course of PVAN is
influenced by primary CMV infection, CMV reactiva-
tion, or by other opportunistic infections.
A number of important questions remain regarding
the long-term function of grafts affected by PVAN. The
6-month follow-up period that we have focused upon
for this analysis, while relatively short, is in keeping with
the reported potential for PVAN to progress rapidly
toward advanced graft dysfunction or graft loss [1–6]. In
addition, we find, in patients diagnosed early by surveil-
lance biopsy, that repeated biopsy within 6 months of
altering immunosuppression can demonstrate signifi-
cantly diminished or even absent viral involvement of
tubular epithelium and improvement in short-term allo-
graft survival. In our cohort of patients, reduced immu-
nosuppression following PVAN diagnosis has not been
associated with an unacceptable rate of acute rejection
(22%). It remains to be seen, however, whether these
patients will suffer higher rates of late acute rejection
or chronic allograft nephropathy compared to those in
whom reduced immunosuppression has not been neces-
sary. In addition, it is not currently known whether re-
lapse of PVAN or progression of interstitial fibrosis fol-
lowing elimination of the virus will be encountered
during prolonged follow-up. For patients in whom graft
loss occurs as a result of PVAN, the risk of recurrence
in a subsequent allograft is also unknown. Short-term
success has been reported for retransplantation [31] but
longer clinical experiences with PVAN will be necessary
before this, and other, important questions are clearly
resolved.
CONCLUSION
Our results point to a number of parameters that are
associated with poor graft outcome in renal transplant
recipients with PVAN. The most important of these is
a delay in diagnosis until clinically apparent graft dys-
function and histologic evidence of chronic interstitial
injury have occurred. We find that surveillance protocol
biopsies allow for detection of invasive BK viral disease
at a subclinical stage and, importantly, we show that
this early diagnosis is accompanied by reduced risk of
subsequent disease progression. We believe that the
widespread availability of noninvasive tests for BK viral
activity, particularly PCR screening of blood, is likely to
provide an additional opportunity for early diagnosis
and management of PVAN but that the predictive value
of these tests must continue to be validated in the context
of histologically confirmed disease.
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